Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD

Chest

Volumn 120, Issue 4, 2001, Pages 1253-1261

  Taylor, James ^a,e   Kotch, Arthur ^b,e   Rice, Kathryn ^c   Ghafouri, Mo ^d   Kurland, Caryn L ^d   Fagan, Nora M ^d   Witek, Theodore J ^d   Allen, Roblee ^e   Amgott, Theodore ^e   Blumberg, Horst ^e   Brazinsky, Shari Anne ^e   Castle, James R ^e   Costantini, Peter J ^e   Ellison, William T ^f   Garcia, Joe ^e   Garland, W Thomas ^e   Goldman, Michael ^e   Jackson, Fredric ^e   Kaye, Mitchell ^e   Knoper, Steven ^e   Kreitzer, Stephen M ^e   Lapidus, Robert ^e   Miller, H Charles ^e   Miller, K Scott ^e   Nicotra, M Brooke ^e   Pichurko, Bohdan ^e   Rice, Kathryn L ^e   Ries, Andrew ^e   Sokolowski, Joseph ^e   Tita, James ^e   Tonner, Michael P ^e   Votteri, Bernhard ^e   Wachtel, Andrew S ^e   Weiss, Laurence A ^g   Wesselius, Lewis ^e   Westerman, Jan ^h   more..

^a Pulmonary Consultants   (United States)

^b DANBURY HOSPITAL   (United States)

^c VA MEDICAL CENTER   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e NONE   (United States)

^f NONE   (United States)

^g NONE   (United States)

^h NONE   (United States)

Author keywords

Chlorofluorocarbon; COPD; Hydrofluoroalkane 134a; Ipratropium bromide

Indexed keywords

CHLOROFLUOROCARBON; FLUORINATED HYDROCARBON; IPRATROPIUM BROMIDE; PROPELLANT;

ADULT; AEROSOL; AGED; AREA UNDER THE CURVE; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LABORATORY TEST; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARAMETER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 17944367198     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.120.4.1253     Document Type: Article

References (21)

1. CFCS and the ozone layer
2. Stratospheric sink for chlorofluoromethanes: Chlorine atom catalyzed destruction of ozone
3. New delivery systems and propellants
4. Twenty-eight-day double-blind safety study of an HFA-134a inhalation aerosol system in healthy subjects
5. Equivalence of asthma control with new CFC-free formulation HFA-134a beclomethasone dipropionate and CFC-beclomethasone dipropionate
6. Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler
7. Proventil HFA provides bronchodilation comparable to Ventolin over 12 weeks of regular use in asthmatics
8. Proventil HFA and Ventolin have similar safety profiles during regular use
9. Proventil HFA provides protection from exercised-induced bronchoconstriction comparable to Proventil and Ventolin
10. Why the environment matters
11. CPMP on possible alternatives to CFCs
12. Management of chronic obstructive pulmonary disease
13. Fifteen-year interval spirometric evaluation of the Oregon predictive equations
14. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD)
15. Standardization of spirometry
16. Approximation of definite integrals: The trapezoidal rule and Simpson's rule
17. The technical transition to CFC-free inhalers
18. Therapeutic equivalence of a novel HFA-134a containing metered dose inhaler and the conventional CFC inhaler (Berodual) for the delivery of a fixed combination of fenoterol/ipratropium bromide: A randomized double-blind, placebo-controlled crossover study in patients with asthma
19. Evaluation of non-chlorofluorocarbon formulation of cromolyn sodium (Intal) metered-dose inhaler versus the chlorofluorocarbon formulation in the treatment of adult patients with asthma: A controlled trial
20. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma
21. Dose response study of ipratropium bromide dry powder (IBDP) in patients with chronic obstructive pulmonary disease (COPD)